Transforming growth factor-β signaling modifies the hematopoietic acute inflammatory response to drive bone marrow failure.
Journal
Haematologica
ISSN: 1592-8721
Titre abrégé: Haematologica
Pays: Italy
ID NLM: 0417435
Informations de publication
Date de publication:
01 06 2022
01 06 2022
Historique:
received:
06
10
2020
pubmed:
29
10
2021
medline:
3
6
2022
entrez:
28
10
2021
Statut:
epublish
Résumé
Bone marrow failure syndromes are characterized by ineffective hematopoiesis due to impaired fitness of hematopoietic stem cells. They can be acquired during bone marrow stress or innate and are associated with driver genetic mutations. Patients with a bone marrow failure syndrome are at higher risk of developing secondary neoplasms, including myelodysplastic syndromes and leukemia. Despite the identification of genetic driver mutations, the hematopoietic presentation of the disease is quite heterogeneous, raising the possibility that non-genetic factors contribute to the pathogenesis of the disease. The role of inflammation has emerged as an important contributing factor, but remains to be understood in detail. In this study, we examined the effect of increased transforming growth factor-b (TGFb) signaling, in combination or not with an acute innate immune challenge using polyinosinc:polycytidilic acid (pIC), on the hematopoietic system without genetic mutations. We show that acute rounds of pIC alone drive a benign age-related myeloid cell expansion and increased TGFb signaling alone causes a modest anemia in old mice. In sharp contrast, increased TGFb signaling plus acute pIC challenge result in chronic pancytopenia, expanded hematopoietic stem and progenitor cell pools, and increased bone marrow dysplasia 3-4 months after stress, which are phenotypes similar to human bone marrow failure syndromes. Mechanistically, this disease phenotype is uniquely associated with increased mitochondrial content, increased reactive oxygen species and enhanced caspase-1 activity. Our results suggest that chronic increased TGFb signaling modifies the memory of an acute immune response to drive bone marrow failure without the need for a preexisting genetic insult. Hence, non-genetic factors in combination are sufficient to drive bone marrow failure.
Identifiants
pubmed: 34706493
doi: 10.3324/haematol.2020.273292
pmc: PMC9152956
doi:
Substances chimiques
Transforming Growth Factor beta
0
Transforming Growth Factors
76057-06-2
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1323-1334Subventions
Organisme : NIDDK NIH HHS
ID : R01 DK102890
Pays : United States
Références
Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2572-6
pubmed: 7708687
FEBS Lett. 2006 May 22;580(12):2811-20
pubmed: 16678165
Nucleic Acids Res. 2010 Jul;38(Web Server issue):W755-62
pubmed: 20513647
Stem Cell Reports. 2016 Jul 12;7(1):11-8
pubmed: 27373927
Int J Mol Sci. 2016 Jun 15;17(6):
pubmed: 27314337
Exp Hematol. 2021 Apr;96:1-12
pubmed: 33571568
Folia Histochem Cytobiol. 2007;45(1):5-14
pubmed: 17378239
Trends Mol Med. 2013 Sep;19(9):513-4
pubmed: 23932594
Exp Hematol. 2011 Jun;39(6):666-675.e1
pubmed: 21447369
Nature. 2015 Apr 23;520(7548):549-52
pubmed: 25707806
J Biol Chem. 2007 Dec 14;282(50):36321-9
pubmed: 17959595
Science. 2016 Apr 22;352(6284):aaf1098
pubmed: 27102489
J Exp Med. 2013 Mar 11;210(3):623-39
pubmed: 23440043
Cell Stem Cell. 2016 May 5;18(5):668-81
pubmed: 27053300
Blood. 2018 Oct 11;132(15):1553-1560
pubmed: 30104218
Cell Stem Cell. 2021 Jan 7;28(1):33-47.e8
pubmed: 32997960
BMC Bioinformatics. 2013 Apr 15;14:128
pubmed: 23586463
Leukemia. 2005 Sep;19(9):1558-66
pubmed: 16034467
Blood. 2010 Aug 26;116(8):1244-53
pubmed: 20489054
Blood Adv. 2019 Sep 24;3(18):2751-2763
pubmed: 31540902
Nature. 2016 Sep 29;537(7622):698-702
pubmed: 27580035
Nat Commun. 2017 Feb 08;8:14382
pubmed: 28176763
Blood. 2015 Aug 27;126(9):1057-68
pubmed: 26077396
Science. 2014 Sep 26;345(6204):1251086
pubmed: 25258085
Exp Hematol. 2018 Mar;59:9-13
pubmed: 29248611
Cancer Res. 2011 Feb 1;71(3):955-63
pubmed: 21189329
Haematologica. 2018 Mar;103(3):417-426
pubmed: 29269525
Cell. 2006 Sep 22;126(6):1135-45
pubmed: 16990137
Nat Immunol. 2009 Mar;10(3):241-7
pubmed: 19221555
Blood Adv. 2019 Dec 23;3(24):4271-4279
pubmed: 31869414
Leukemia. 2019 Jun;33(6):1303-1312
pubmed: 30962581
Semin Hematol. 2019 Jan;56(1):69-82
pubmed: 30573048
Blood. 2008 Oct 15;112(8):3434-43
pubmed: 18474728
Cell. 2011 Nov 23;147(5):1146-58
pubmed: 22118468
Stem Cells Dev. 2004 Oct;13(5):536-47
pubmed: 15588511
Curr Stem Cell Rep. 2016 Dec;2(4):388-397
pubmed: 28529843
Blood. 2019 Jan 10;133(2):107-120
pubmed: 30413413
Front Physiol. 2014 Sep 29;5:352
pubmed: 25324778
Science. 2014 Sep 26;345(6204):1250684
pubmed: 25258083
Blood. 2002 Nov 15;100(10):3495-503
pubmed: 12393681
Cell Stem Cell. 2020 Mar 5;26(3):420-430.e6
pubmed: 32059807
Blood. 2013 Oct 31;122(18):3197-205
pubmed: 24046015
Redox Biol. 2019 Sep;26:101255
pubmed: 31247505
Toxicol In Vitro. 2013 Aug;27(5):1542-9
pubmed: 23542209
Haematologica. 2018 Sep;103(9):1462-1471
pubmed: 29773599
Mitochondrion. 2018 Jul;41:21-27
pubmed: 29246869
Hematology Am Soc Hematol Educ Program. 2002;:136-61
pubmed: 12446422
Blood Rev. 2019 Mar;34:1-15
pubmed: 30314642
Stem Cells Dev. 2004 Feb;13(1):27-38
pubmed: 15068691
J Clin Invest. 2019 Jun 18;129(9):3821-3826
pubmed: 31211692
Lab Invest. 2010 Apr;90(4):543-55
pubmed: 20142803
J Clin Invest. 2004 Mar;113(5):676-85
pubmed: 14991065
Blood. 2016 Dec 22;128(25):2960-2975
pubmed: 27737891
Blood. 2013 Apr 11;121(15):2875-81
pubmed: 23390194